Clinical trials in Ukraine: clinical sites demonstrate reliability in active clinical trials and readiness to participate in new ones

In 2025, the EBA Clinical Trials Subcommittee continued its annual assessment of clinical trial sites in Ukraine, which is conducted in the context of a full-scale war.

The survey covered 76 clinical sites across the country (excluding temporarily occupied territories), including Kyiv, Lviv, Vinnytsia, Kharkiv, Dnipro, among others, and showed an overall positive trend.

Compared to 2024, the proportion of clinical sites with active clinical trials rose to 91% in 2025. All respondents (100%) confirmed their full operational capacity under current conditions, exceeding previous years’ indicators. They reported uninterrupted functioning, readiness to conduct new clinical trials, and a high level of engagement.

Almost all clinical sites (75 out of 76) operate according to a standard schedule and have sufficient qualified staff for investigational teams. Workload assessment revealed that only 3% of sites are highly loaded, and 76% operate at a regular pace, while, 20% reported underutilization, indicating potential for expanded participation in future clinical trials.

Nearly all respondents (99%) observed improvements in the supply of investigational drugs, biosample logistics, and interactions with local ethics commissions. None of clinical sites reported restrictions on monitor visits, further confirming the stability of their operations.

50% of clinical sites reported an increase in the patient pool, and another 47% - about a stable sufficient level of patient pool - suggesting promising prospects for future recruitment.

The proportion of sites initiating new trials (startup stage) continues to grow: 57% in 2025, compared to 53% in 2024 and 37% in 2023. Additionally, the share of clinical sites, where the feasibility of conducting clinical trials is assessed, has increased to 80%.

The most common therapeutic areas include gastroenterology, rheumatology, cardiology, endocrinology, pulmonology, neurology, and oncology. Notably, 71% of sites specialize in multiple areas, demonstrating their versatility and readiness for diverse clinical trials.

The EBA Clinical Trials Subcommittee sincerely thanks the clinical sites for participating in the survey and extends its gratitude to all investigators for their dedication and daily efforts in sustaining, restoring, and advancing clinical trials in Ukraine.

The results of this survey once again confirm that clinical sites in Ukraine are actively operating, demonstrating high reliability and interest, and possess real capabilities and long-term potential for continued involvement in active and new international multicenter clinical trials across various therapeutic areas.

The results of the 2024 Clinical Trials Sites status survey — at the link

The results of the 2023 Clinical Trials Sites status survey — at the link